Olodaterol is a novel inhaled long-acting β 2 -agonist (LABA) that showed efficacy as a bronchodilator for patients with chronic obstructive pulmonary disease (COPD) and asthma. However, it is unclear whether olodaterol reduces mortality; the safety issues of olodaterol have not been fully evaluated.
Introduction
Inhaled long-acting β 2 -agonists (LABAs) represent an important class of drugs in the treatment of chronic obstructive pulmonary disease (COPD) and asthma [3, 4] . The bronchodilator effects of LABAs are mainly due to the relaxation of airway smooth muscle following increased production of cAMP by adenylyl cyclase, activation of protein kinase A and elevation of intracellular calcium levels [5] . Inhaled LABAs with or without inhaled corticosteroids (ICS) can reduce the risk of acute exacerbations of COPD and improve lung function and quality of life in COPD patients [6, 7] . In asthma, inhaled LABAs in combination with an ICS provide improved symptom control and decreased risk of exacerbation [8, 9] . Inhaled LABAs without ICS for chronic asthmatics also show efficacy in morning peak expiratory flow rate, asthma symptoms, quality of life and reduction of rescue medication [10] . However, for asthma patients, LABA alone without ICS is not recommended in the guidelines [4] because of concerns regarding the possibility of increase in mortality [11] .
Olodaterol (BI 1744 or BI 1744 CL) is a novel inhaled LABA that has a duration of action of >24 h [12] . It is distinguished from other inhaled β-agonists by its high selectivity for β 2 adrenergic receptors in the airway [13] . Various trials have suggested that olodaterol can significantly improve lung function and quality of life in patients with moderate to severe COPD [14] [15] [16] [17] , and it has also shown a bronchodilating effect in patients with moderate or severe persistent asthma [18, 19] . However, it is unclear if olodaterol reduces mortality risk, which is one of the major therapeutic targets, in either COPD patients or asthmatics. Rather, the number of deaths was greater in the olodaterol arm compared to placebo of several large randomized controlled trials (RCTs) that included COPD patients [16, 17, 20] . Although the risk of death was not significantly increased in an analysis of four olodaterol-related clinical trials [21] , there has not been a systematic review including all relevant studies that evaluates the incidence of death and serious adverse events (SAEs) in COPD and asthma patients using olodaterol. Additionally, there has been concern that the incidence of death and acute exacerbation may be increased when asthma patients use LABAs [11] . Finally, the effect of olodaterol on SAEs has never been reported.
We conducted this systematic review and meta-analysis to examine the impact of inhaled olodaterol on mortality and SAEs in patients with COPD or asthma.
Methods

Search strategy and selection criteria
We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and conference abstracts from the international congress of the American Thoracic Society, British Thoracic Society and European Respiratory Society up to 22 nd September 2015 using the search terms: "Olodaterol," "Striverdi," "BI 1744" or "BI 1744 CL," and "6-hydroxy-8-
The inclusion criteria were as follows: (i) COPD or asthma patients older than 18 years; (ii) studies comparing olodaterol with placebo or olodaterol plus tiotropium with tiotropium; (iii) parallel or crossover RCTs; and (iv) studies presenting mortality or SAEs in published articles, ClinicalTrials.gov or conference abstracts. We defined the olodaterol arm as patients who were randomly allocated to an olodaterol group or an olodaterol plus tiotropium group and the placebo arm as those in the placebo group or the tiotropium group.
Searched studies were reviewed and selected according to the inclusion criteria. Study selection was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [22] . Any discrepancy of opinions in the inclusion or exclusion of the studies was resolved by referring to the original articles and discussing them as a group.
Data extraction and assessment of the risk of bias
We collected the baseline data of each study including study ID number, year of publication, study design, number of participants, inclusion criteria, and exclusion criteria. The extracted patient data were age, sex, smoking history (pack years), type of respiratory disease (COPD or asthma), prebronchodilator forced expired volume in 1 s (FEV 1 ) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage (COPD patients only). We also noted the method of intervention in each study, the dose of olodaterol, the treatment duration and treatment regimen, the use of other concomitant drugs such as ICS and methylxanthines, and the type of inhalation device.
The risk of bias in each study was assessed in seven dimensions according to the Cochrane risk of bias tool: (i) adequacy of random sequence generation; (ii) appropriateness of allocation concealment; (iii) sufficient blinding of participants and researchers; (iv) adequate blinding of outcome assessment; (v) completeness of outcome data; (vi) selective reporting; and (vii) other causes of bias. We resolved any disagreement in the risk of bias assessment by discussion.
Primary and secondary outcomes
The primary outcome was the risk of mortality in the olodaterol arm vs. the placebo arm (olodaterol vs. placebo or olodaterol + tiotropium vs. placebo + tiotropium; same dose of tiotropium was compared in each trial). The secondary outcome was comparison of the risk of nonfatal SAEs between the olodaterol and the placebo arms. In addition, total adverse events (AEs), AEs requiring hospitalization, and treatment-related AEs were analysed.
Statistical analysis
We conducted a metaregression analysis to estimate the odds ratio (OR) and 95% confidence interval (CI) using the Peto OR method and the fixed effect model. The chi-square test was used to find and measure quantitative heterogeneities among the pooled data. We assessed publication bias by funnel plot. We incorporated crossover trials in a meta-analysis by taking all participants and measurements from olodaterol periods as well as the placebo periods, and all studies were considered as if they were parallel trials.
Subgroup analyses of mortality and nonfatal SAEs were conducted according to treatment regimens, type of respiratory disease, and use of other bronchodilators. Metaregression was performed to examine the correlation between the risk of mortality or nonfatal SAEs and the dose of olodaterol or the treatment duration, or prebronchodilator FEV 1 . Meta-analysis, chi-square test for heterogeneity, and funnel plot were conducted with Review Manager, version 5.3 (Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014). Metaregression analysis was implemented by the STATA version 13.1 (STATA Corp., College Station, TX, USA).
Results
The database search protocol identified 48 articles in MEDLINE, 108 in EMBASE, 64 in the Cochrane Library, 54 in ClinicalTrials.gov, 34 in the American Thoracic Society abstracts, 18 in the British Thoracic Society abstracts and 32 in the European Respiratory Society abstracts. Among them, there were 26 that met the inclusion criteria (PRISMA guideline, Figure 1 ). Data regarding deaths were available for 18 of the 26 included trials, while all of trials reported data regarding SAEs. The risk of bias was generally low among the included trials ( Figure S1 ). Publication bias was not indicated in the funnel plot for the olodaterol arm and mortality ( Figure S2 ).
Description of the included studies
The included studies consisted of eight parallel trials and 18 crossover trials ( Table 1) . Most of the trials were published between 2014 and 2015. Among 16 591 participants who were included, 9855 were in the olodaterol arm and 6736 were in the placebo arm. Olodaterol was compared with placebo in 17 trials, while olodaterol plus tiotropium was compared with tiotropium in nine trials. The dose of olodaterol was 2-20 μg, and the duration of treatment ranged from 1 day to 52 weeks. Crossover studies had washout periods of at least 2 weeks between interventions. All but two (1222.51 and 1222.52) trials permitted the use of an ICS as maintenance therapy during the study period. Soft mist inhaler was predominantly used through all the included trials, but dry powder inhaler was also applied in the two trials (1222.51 and 1222.52). Olodaterol was always administered by soft mist inhaler and dry powder inhaler was used to administer tiotropium.
There were 14 915 COPD patients and 1673 asthma patients. COPD patients were aged 40 years or older with >10 pack years of smoking history, while the asthma patients were aged 18 years or older and had smoking histories of <5 or 10 pack years. The mean age of COPD patients ranged between 60.6 and 69.3 years while that of asthma patients was between 28.9 and 45.3 years. The majority of COPD patients (53-95%) were men and the GOLD stage was 2-4. The mean prebronchodilator FEV 1 of COPD subjects ranged between 37% and 50%. COPD trials have a crossover or parallel design with various durations of intervention from 1 day to 1 year. However, all the asthma trials were conducted by a crossover method with relatively short duration, up to 16 weeks. The dose of ICS used by asthma patients was not mentioned in the report or article, although all the asthma trials included only stable patients who used moderate to high doses of ICS or low doses of ICS combined with an LABA.
Risk of mortality in the olodaterol arm compared to the placebo arm
Eighteen studies were assessed to compare the risk of mortality between the olodaterol and the placebo arms ( Figure 2 ). The olodaterol arm had a higher OR for death, but there was no statistically significant difference in the death rates (Peto fixed OR 1.31; 95% CI 0.90-1.89). Heterogeneity was not observed (I 2 = 0%, P = 0.94). Subgroup analyses according to the treatment regimen, type of respiratory disease, and use of an ICS or a methylxanthine showed similar results in each group ( Figures S3-S6 ). No deaths were reported in asthma patients; however, in COPD patients, 75 (1%) patients in the olodaterol arm and 45 (1%) patients in the placebo arm died. No deaths were recorded in COPD patients who did not use concurrent methylxanthines. According to the metaregression analysis, there was no significant association between the risk of mortality (log OR) and treatment duration or olodaterol dosage (Table S1 and Figure S7 ). We observed no significant relationship between baseline FEV 1 and mortality in the metaregression analysis (data not shown).
Risk of nonfatal SAEs in the olodaterol arm compared to placebo arm
The meta-analysis (26 trials) indicated that the risk of nonfatal SAEs in the olodaterol arm was not significantly higher compared to the placebo arm (Peto fixed OR 1.03; 95% CI 0.91-1.15; Figure 3 ). Heterogeneity among the trials was not suspected (I 2 = 0%, P = 0.88). Subgroup analyses according to treatment regimen, type of respiratory disease, and use of an ICS or methylxanthine had similar results in each group ( Figures S8-S11 ). About 0.4% of asthma patients experienced nonfatal SAEs, while 9% of COPD patients had at least 1 nonfatal SAE. Eight trials were excluded from the subgroup analysis of the use of other bronchodilators because data regarding the use of an ICS or a methylxanthine were not available. We did not find an association between the risk of SAEs (log OR) and treatment duration or olodaterol dosage (Table S2 and Figure S12 ). There was no significant relationship between baseline FEV 1 and SAEs (data not shown). The AEs considered as nonfatal are described in Table S3 .
Comparison of the risk of other AEs in the olodaterol and placebo arms
The risk of total AEs was similar between olodaterol and placebo arms in the present meta-analysis (Peto fixed OR 1.00; 95% CI 0.93-1.08; Figure S13 ). Statistically consistent results were observed in the 26 included studies (I 2 = 0%, P = 0.50).
Only four trials were found to report AEs requiring hospitalization. The hospitalization rate was not significantly different between the two arms (Peto fixed OR 0.98; 0.84-1.14; Figure S14 ). No evidence of heterogeneity for the rate of hospitalization was detected (I 2 = 10%, P = 0.33). Twelve trials recorded the incidence of treatment-related AEs. The risk of Figure 1 PRISMA flow chart for the meta-analysis Figure S15 ). Major heterogeneity among trials was not detected (I 2 = 34%, P = 0.13).
Discussion
Inhaled olodaterol did not have a significant effect on the risk of mortality in a clinical trial population with COPD and asthma. Subgroup analysis showed that the OR for mortality in the olodaterol arm was not affected by dose, treatment regimen, treatment duration, type of respiratory disease or use of an additional bronchodilator. There was no significant association between the risk of mortality and the dose of olodaterol or treatment duration. Meta-analyses of nonfatal SAEs did not reveal any significantly harmful effect of olodaterol compared to placebo. Other AEs such as total AEs, AEs requiring hospitalization and treatment-related AEs did not differ according to the type of intervention.
The role of LABAs in reducing the risk of acute exacerbations and improving FEV 1 or quality of life in patients with COPD has been well studied [6, 7] . In addition, in the TORCH trial, salmeterol was found to have a beneficial effect on survival in patients with moderate to severe COPD [23] . In the present study, inhaled olodaterol neither significantly reduced nor increased the risk of mortality within the context of clinical trials conducted on patients with COPD and asthma. Nonetheless, we cannot completely exclude the possibility of a higher mortality risk with inhaled olodaterol because the OR for mortality was 1.31 and the 95% CI (0.90-1.89) was wide.
In fact, for the studies involving asthma patients, no deaths were recorded in the treatment arms or the control arms. Considering that the reduction of mortality is one of the major therapeutic concerns for patients with COPD, a consistent OR of >1.00 is sufficient to raise concerns [3, 4, 24] .
We could not find any systematic review with a metaanalysis conducted to investigate the relationship between olodaterol and mortality/nonfatal AEs. One pooled analysis reported that the incidence of death or SAEs was balanced across the intervention arms: placebo, formoterol and olodaterol [21] . This pooled analysis includes four trials (1222.11, 1222.12, 1222.13, and 1222.14) that were conducted for 48 weeks. However, the pooled analysis also showed a high OR (>1) for mortality (Peto fixed OR 1.25; 95% CI 0.65-2.39). Our systematic review included all the studies conducted for at least 4 weeks. It is possible that a study of longer duration could show the relationship between drug treatment and SAEs, including death. However, we think, in any case, '48 weeks' is not enough for investigating the mortality outcome. At least 3 years are required to investigate the efficacy outcome of 'altering disease progression' [25] . In addition, theoretically, the AEs of olodaterol can be triggered by a single dose. According to a recent review article, olodaterol reaches the maximum plasma concentration within 10-20 minutes of inhalation, with a bioavailability of about 30% [26] . There were sudden AEs such as respiratory compromise, which could be The published baseline data of 1237.5 and 1237.6 are described as a single table in which the data cannot be separately assessed.
c
The published baseline data of 1237.25 and 1237.26 are described as a single table in which the data cannot be separately assessed.
Olodaterol and mortality induced within a short duration of drug treatment (1222.3). In the subgroup analysis, trials with longer duration (> 12 weeks) showed a result similar to that of the analysis for all trials.
Inhaled olodaterol is delivered through a soft mist inhaler device. These devices can provide more efficient delivery of the aerosol to the lungs compared to conventional devices, which may be of benefit to patients who cannot generate
Figure 2
Mortality Figure 3 Serious adverse events high inspiratory flow, even though it may present a higher risk of AEs for those who do generate high flow [27] . It is possible that a similar issue could arise with olodaterol. However, the high OR reported herein may also reflect some element of bias. First, we failed to show a significant association between the risk of mortality and the dose and duration of olodaterol treatment in the metaregression analysis, although more mortality cases were identified in trials with a study duration >12 weeks than in those with a duration <12 weeks. Second, the mortality rates of olodaterol group in the trials included in our systematic review were comparable to previous trials with other LABAs; 0-3% in trials comparing LABA and placebo, and 0-3% in trials comparing LABA + tiotropium and placebo + tiotropium [28, 29] .
No deaths were observed in studies of asthmatics, which could be explained by the fact that asthma participants were younger (mean 44-45.3 years old vs. mean 60.6-69.3 years old in COPD participants) and had better lung function (mean FEV 1 % 62-64% vs. mean FEV 1 % 37-53% in COPD participants). In addition, the study duration of asthma trials was short (maximum 16 weeks). Notably, in COPD patients, deaths were reported in participants who were allowed to be treated with methylxanthines. Although an old study reported that the concomitant use of β agonists and methylxanthines is capable of producing myocardial necrosis and an increase in the development of cardiac arrhythmias in several species of animals [30] , we did not find any evidence in human studies suggesting an interaction between olodaterol and methylxanthines. Moreover, we were not aware of how many patients were actually treated with methylxanthines in the studies.
The limitations of the present systematic review are as follows: first, SAEs and treatment-related AEs were not clearly defined among the included studies and were determined according to the subjective standard of each researcher. Second, we do not know exactly how many patients in each arm used other bronchodilators. Most of the trials reported the baseline pulmonary medications of the included patients, but we could not confirm that the patients used them in the same manner. In addition, the dose of ICS used by the asthma patients was not recorded in the included studies. Third, we cannot exclude the possibility of confounding between the severity of disease and use of ICS or methylxanthines in COPD patients. Fourth, many of the included trials did not describe the method of allocation concealment, and those studies were considered to have an unclear risk of selection bias. Fifth, the trials with 1-day treatment may have been too brief to demonstrate a difference in the mortality rates between two arms [25] , even when they attempted to define it. Nonetheless, we chose to include these studies because cardiac events can be triggered by a single dose of a β-agonist [31] . Sixth, inclusion of crossover trials could lead to unitof-analysis error [32] , although the meta-analysis including parallel studies alone showed similar results. Seventh, the causes of death were not assessed.
Conclusions
Inhaled olodaterol has no impact on mortality and nonfatal serious adverse events in clinical trials conducted on patients with COPD and asthma. However, the interpretation is limited by a high OR (1.31) and a wide CI for mortality that includes the hazardous effect. Further long-term, large clinical trials are needed for safety concerns.
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